Skip to main content
Erschienen in: BMC Gastroenterology 1/2022

Open Access 01.12.2022 | Case report

Cholangiocarcinoma presenting as dysphagia and misdiagnosed as gastritis: a case report

verfasst von: Chao Wang, Baoyue Zhang, Runmei Peng, Zan Zuo, Hongzhong Cheng, Jun Zhu, Tianxing Chen, Zhengji Song

Erschienen in: BMC Gastroenterology | Ausgabe 1/2022

Abstract

Background

Heterotopic tumor is a rare disease. Thus far, no cases of heterotopic cholangiocarcinoma have been reported in the world. Cholangiocarcinoma mainly metastasizes by direct invasion, and it can lead to liver metastasis in its advanced stage. There were few clinical cases of gastric metastasis in advanced tumors, mainly seen in breast cancer, lung cancer, liver cancer, malignant melanoma, choriocarcinoma, and hematological tumors. Metastases of cholangiocarcinoma to the stomach also are exceptionally rare.

Case presentation

A 58-year-old man was admitted to the hospital because of difficulty swallowing for one year. Upon gastroscopy, we found the tumor at the region of the cardia and gastric fundus. Macroscopical appearance of the tumor suggested its malignant nature. Computed tomography (CT) findings showed that the wall of the cardia, fundus, and stomach body were thickened, suggesting a tumor. Because the patient had obvious difficulty swallowing, we invited cardiothoracic surgeons for consultation. They considered that the patient had definite mechanical obstruction in the lower esophagus; hence, they performed an operation. Immunohistochemical staining revealed low-to-medium differentiated adenocarcinoma (containing mucinous adenocarcinoma components) of biliary origin.

Conclusions

We highlight the importance of the endoscopic biopsy of gastric tumor. However, when its results are inconsistent with the clinician’s judgment, further examination is required. Endoscopic ultrasonography and enhanced CT may be a good choice. If necessary, on the premise of patient acceptance, the diagnosis could be confirmed after surgical excision. Here we report a case of a patient with heterotopic cholangiocarcinoma in the gastric fundus. The most common tissue ectopias in the digestive tract include esophagogastric gastric mucosal ectopia, duodenal gastric mucosal ectopia, and gastric mucosal small intestinal ectopia. Thus far, there have been no reports of ectopic cholangiocarcinoma and associated cancer in the stomach. In addition, metastases of cholangiocarcinoma to the stomach are also exceptionally rare, and most of them are due to a direct invasion. The discovery of the primary lesion is an important clue for the reliable diagnosis in such cases.
Hinweise
Chao Wang and Zhengji Song are first authors

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CT
Computed tomography
BMI
Body Mass Index
SCJ
Squamous and columnar epithelial junction
DL
Demarcation line
NBI
Narrow band imaging
HE
Hematoxylin–eosin

Background

Heterotopic tumor is a rare disease. Thus far, no cases of heterotopic cholangiocarcinoma have been reported. Patients with cholangiocarcinoma inside and outside the liver generally have abnormal liver function and symptoms of biliary obstruction, such as jaundice and itchy skin. Some patients may also have pain in the liver area [1]. The disease often has a high degree of malignancy [2, 3]. The main way of metastasis of cholangiocarcinoma is direct invasion, and liver metastasis can develop in the advanced stage. There have been few clinical cases of gastric metastasis in advanced tumors, mainly in breast cancer, lung cancer, liver cancer, malignant melanoma, choriocarcinoma, and hematological tumors. Metastases of cholangiocarcinoma to the stomach are exceptionally rare.

Case presentation

A 58-year-old man was admitted to the hospital because of difficulty swallowing.
One year before the current admission, the patient noticed dysphagia when eating solid food, cough after drinking water, and belching. Since these symptoms were not getting worse and did not affect his daily life, the patient ignored them and did not ask for medical help.
Five months before the current admission, since the symptoms did not alleviate, the patient underwent gastroscopy at the outpatient clinic of another hospital. The gastroscopy report revealed a tumor at the region of the cardia and gastric fundus. The biopsy was obtained and showed signs of acute and chronic inflammation and active glandular hyperplasia at the gastric fundus. Since cancer was suspected, the physicians recommended obtaining another biopsy and transferring the patient to our hospital for further treatment, but the patient did not comply. He took omeprazole himself, but his symptoms never improved.
Eight weeks before the current admission, concerned with lack of significant improvement in his symptoms, the patient came to our hospital for the first time. The patient's weight dropped 3 kg compared with that in the time of his last visit of the clinic. On gastroscopy, we found a tumor at the region of the cardia and gastric fundus. Macroscopical appearance of the tumor suggested its malignant nature. Given that pathological results did not support cancer, the patient refused surgical exploration and requested to continue medical treatment and follow-up at the outpatient clinic. We instructed the patient to eat a liquid diet and take the following medications: esomeprazole enteric-coated tablets (20 mg po bid) to inhibit gastric acid secretion, almagate (1.5 g po tid) to protect gastric mucosa, and mosapride citrate (5 mg po tid) to promote gastrointestinal motility, and other methods for symptomatic treatment.
One week before this admission, the patient felt worsened dysphagia, with difficulty in eating a liquid diet, accompanied with nausea and vomiting. His weight was 5 kg lower than before [only 40.5 kg, Body mass index (BMI): 15.5 kg/m2]. Since the symptoms did not improve for a week, he revisited our hospital. We worried about the patient’s tumor progression. The patient was scheduled for gastroscopy and enhanced CT again, and a jejunal nutrition tube was placed using endoscopy. Because the patient had obvious difficulty swallowing, we invited cardiothoracic surgeons for consultation. They considered that the patient had definite mechanical obstruction in the lower esophagus; hence, they operated on the patient.

Diagnostic Assessment

Physical examination

Superficial lymph nodes throughout the body were not enlarged. Slight tenderness was present in the upper abdomen.

Blood examinations

The patient underwent two successive blood examinations in our hospital (including blood cell test, liver enzymes, and tumor markers). Only one test result was obviously abnormal. Reference range of carbohydrate antigen 724 is 0.0–6.7 U/ml in our hospital. The patient's results were 17.9 U/ml (8 weeks before admission) and 67.77 U/ml (at the current admission). Reference range of alpha fetoprotein is 1.09–8.04 ng/ml in our hospital. The patient's results were 2.90 ng/ml (8 weeks before admission) and 3.13 U/ml (at the current admission). Reference range of carcinoembryonic antigen is 0.0–5.0 ng/ml in our hospital. The patient's results were 1.13 ng/ml (8 weeks before admission) and 1.58 U/ml (at the current admission). Reference range of carbohydrate antigen 199 is 0–37 U/ml in our hospital. The patient's results were 22.03 U/ml (8 weeks before admission) and 12.04 U/ml (at the current admission).

Endoscopy

During the first gastroscopy, we found a lesion in form of a growing ring around the cardia. The boundary line of the lesion was clear, and it was growing along the lesser curvature distally. There were obvious mucosal swelling, spotty redness, and hyperemia on the surface of the lesion (Fig. 1). Our endoscopic diagnosis was the tumor in the gastric fundus and cardia requiring precise diagnosis (likely a nidus under the mucosa).
During the second gastroscopy, we felt obvious resistance when passing the cardia, which may explain the reported worsening of dysphagia. When the gastroscope entered the stomach cavity, we found that the scope of the lesion had expanded since the last time; the most obvious was the spread to the far side, and rough mucosa of the lesion’s surface, erosion, and secretions could be seen (Fig. 2).

Endoscopic ultrasonography

Eight weeks before the current admission, we performed ultrasound gastroscopy to understand the source of the lesion and the depth of infiltration (Fig. 3). We used miniature probe endoscopic ultrasonography. Ultrasound gastroscopy offered the following diagnosis: the tumor of fundus-cardia (T3–T4 stage).

Radiological examination

Figure 4 shows the enhanced CT picture of the patient in this re-examination.

Therapeutic intervention

Operation

Because the patient’s obstruction site was close to the lower esophagus, our surgical method was based on the transthoracic treatment method for the lower esophageal cancer. During exploration of the lungs and pleura of the left chest cavity, no obvious nodules were seen, and there were no enlarged lymph nodes near the esophagus. We continued to cut the diaphragm and esophageal hiatus about 8 cm, lifted the diaphragm, and observed swollen gastric lymph nodes near the cardia, as well as thickened, stiff and rough stomach wall at the fundus but without adhesions to the surrounding tissue. Figure 5 illustrates the view at surgical procedure. In Fig. 5A, we lifted the stomach wall at the lesion site with hemostatic forceps. The mass of the stomach wall could be moved. In Fig. 5B, the surface was uneven, and many blister-like protrusions of different sizes were visible on the surface. The local area was of a darker color and resembled the skin of a toad. The boundary between the lesion and the normal stomach wall was clear. In Fig. 5C, it shows the overall of the lesion. Considering that the patient had prominent gastric fundus lesions, for safety reasons, we invited a general surgeon (Dr Zhu Jun) to assist. Under his guidance, we removed the lesion with a disposable intraluminal cutting stapler and a disposable endoscopic cutting stapler, and anastomosed the esophagus with the distal stomach. The omentum and the pleura were suspended at the anastomosis to embed it. We sutured the stomach and diaphragm to fix the stomach. We placed a drainage tube between the sixth and seventh ribs. In Fig. 6A and B, the length of the lesion exceeds a 10ml syringe. In Fig. 6C, observation of the excised gastric tumor showed yellowish interstitial fluid exudation and many voids on the cut surface of the stomach wall, resembling a waffle. After the operation, the patient received intravenous drip of antibiotics for 3 days to prevent infection, the intravenous drip of omeprazole to inhibit the secretion of gastric acid, and an intramuscular drug to relieve pain. The patient was asked to fast and was given energy, water, and electrolytes by intravenous drip, water, and electrolytes.
Figure 6 shows the gross appearance of the excised specimen.

Pathohistology

Figure 7 shows the Hematoxylin–eosin (HE) staining of the surgically excised lesion. The pathohistological diagnosis was as follows: (most of the stomach) low-to-medium differentiated adenocarcinoma (including mucinous adenocarcinoma). Neural invasion was found, the serous layer was invaded, the two ends were negative, and the upper esophageal margin and the esophageal abdominal cavity were negative.
The following immunohistochemical profile was obtained: (most of the stomach) Ki-67 (about 30%+), LCK (+), Vim (−), TTF-1 (−), HER-2 (weak positive), Hepa (local positive), PSAP (−), villin (+), CEA (local positive), CK19 (+), CK7 (+), CK20 (−), CDX-2 (focal positive). As shown in Fig. 8, immunohistochemical staining results support low-to-medium differentiated adenocarcinoma (containing mucinous adenocarcinoma components) of biliary origin.

Definite diagnosis

Heterotopic cholangiocarcinoma in the gastric fundus. The patient had no distant metastasis, and two lymph nodes metastasis in the postoperative specimens, So the stage of the tumor is the IIIA stage: T4aN1M0.

Follow-up and outcomes

Patients with cholangiocarcinoma inside and outside the liver generally have abnormal liver function and symptoms of biliary obstruction, such as jaundice and itchy skin. Some patients may also have pain in the liver area [1]. However, our patient’s onset site was in the stomach, and he only had difficulty swallowing. Postoperative pathohistological analysis confirmed cholangiocarcinoma, and although we did not find evidence of distant metastases, in view of high degree of malignancy of this disease [2, 3], we recommended continued chemotherapy to extend survival [4, 5]. However, the patient refused because of the cost of chemotherapy and died nearly five months after the operation.

Discussion and conclusions

It has been reported that a constricting tumor at the gastroesophageal junction with probable invasion of the vagus nerves leads to features of achalasia and gastroparesis. The patient can also present with dysphagia [6, 7]. Such patients are without organic obstruction, but with signs of achalasia, such as beak sign on barium meal examination. Special manifestations may also appear during gastroscopy, including food residues in the esophageal cavity, dilatation of the esophageal cavity, rhythmic contraction rings in the esophagus, and resistance when endoscope passes through the cardia. However, the only manifestation in our patient on gastroscopy was that there was a sense of resistance when the gastroscope passed through the cardia. We considered it a sign of organic obstruction caused by the tumor compressing the cardia.
In fact, it is not uncommon to observe thickening of the stomach wall or gastric mucosa through endoscopy or CT. In such cases, we should consider most commonly H. pylori infection caused mucosal hypertrophy, followed by submucosal infiltration of poorly differentiated gastric cancer, and more rarely, gastric metastases, gastric lymphomas, Menetrier disease, Zollinger-Ellison syndrome, eosinophilic gastritis, gastric tuberculosis, and gastric sarcoidosis. Most of these diseases can be confirmed by endoscopic biopsy.
In the majority of the middle-aged and elderly patients, gastric cancer develops through atrophic gastritis-intestinal metaplasia-atypical hyperplasia-gastric cancer sequence, and Helicobacter pylori infection plays an important role in this process [8]. There have been reports of ectopic gastric mucosa in the bile duct [9], and even of the development of cholangiocarcinoma due to gastric mucosal ectopia [10]. We reviewed the relevant literature and did not find any reports of intragastric bile duct ectopia or intragastric cholangiocarcinoma. However, Japanese scholars have reported [11] a case of cholangiocarcinoma with intragastric metastasis after radical operation, indeed a very rare finding. By reviewing the two gastroscopic images of the patient, we can infer that the growth of this lesion at least started from the submucosa of the stomach and gradually infiltrated into the surface and serosa, which is similar to the growth process of gastric undifferentiated carcinoma. We have three assumptions about the etiology and pathogenesis of this tumor in our patient: The first possibility is based on ectopic intragastric bile duct cells. These abnormal cells turn into cancer cells after abnormal stimulation. The patient had a longer course of disease, combined with the normal bile duct appearance in CT and postoperative pathological findings of cholangiocarcinoma cells. So, we think that this assumption is most likely. The second possibility highlights that environmental factors may govern fully differentiated cells to undergo metaplasia and can cause such diseases, just like intestinal metaplasia. The third explanation may be that this was the metastasis of a cholangiocarcinoma to the stomach, although we think this option is less likely.
Finally, we highlight the importance of the endoscopic biopsy of the gastric tumor. However, when its results are inconsistent with the clinician’s judgment, further examination is required. Endoscopic ultrasonography and enhanced CT may be a good choice. If necessary, on the premise of patient acceptance, the diagnosis could be confirmed on surgically excised lesions. Here, we reported a case of a patient with heterotopic cholangiocarcinoma in the gastric fundus. The most common tissue ectopias in the digestive tract include esophagogastric gastric mucosal ectopia, duodenal gastric mucosal ectopia, and gastric mucosal small intestinal ectopia. So far, there have been no reports of ectopic cholangiocarcinoma and associated cancer in the stomach. In addition, metastases of cholangiocarcinoma to the stomach are exceptionally rare, and most of them are due to a direct invasion. The discovery of the primary lesion is an important clue for the reliable diagnosis in such cases.

Acknowledgements

Not applicable.

Declarations

All the procedures have been performed in accordance with the Helsinki Declaration of 1964 and later versions. Ethics Committee approval was unnecessary for this manuscript because it is a clinical case report only.
Written informed consent for publication of their clinical details and clinical images was obtained from the patient. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73.CrossRef Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73.CrossRef
2.
Zurück zum Zitat Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2(2):58–64.CrossRef Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2(2):58–64.CrossRef
3.
Zurück zum Zitat Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345-348.CrossRef Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345-348.CrossRef
4.
Zurück zum Zitat Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17(1):13.CrossRef Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17(1):13.CrossRef
5.
Zurück zum Zitat Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.CrossRef Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.CrossRef
6.
Zurück zum Zitat Ghoshal UC, Sachdeva S, Sharma A, Gupta D, Misra A. Cholangiocarcinoma presenting with severe gastroparesis and pseudoachalasia. Indian J Gastroenterol. 2005;24(4):167–8.PubMed Ghoshal UC, Sachdeva S, Sharma A, Gupta D, Misra A. Cholangiocarcinoma presenting with severe gastroparesis and pseudoachalasia. Indian J Gastroenterol. 2005;24(4):167–8.PubMed
7.
Zurück zum Zitat Leung VK, Kan PS, Lai MS. Cholangiocarcinoma presenting as pseudoachalasia and gastroparesis. Hong Kong Med J. 2003;9(4):296–8.PubMed Leung VK, Kan PS, Lai MS. Cholangiocarcinoma presenting as pseudoachalasia and gastroparesis. Hong Kong Med J. 2003;9(4):296–8.PubMed
8.
Zurück zum Zitat Lai S. A human mode of intestinal type gastric carcinoma. Med Hypotheses. 2019;123:27–9.CrossRef Lai S. A human mode of intestinal type gastric carcinoma. Med Hypotheses. 2019;123:27–9.CrossRef
9.
Zurück zum Zitat Sciarra A, Hessler R, Godat S, Fraga M, Dromain C, Duran R, Halkic N, Sempoux C. Heterotopic gastric mucosa in a duplication cyst of the common hepatic duct mimicking cholangiocarcinoma. Int J Surg Pathol. 2018;26(1):84–8.CrossRef Sciarra A, Hessler R, Godat S, Fraga M, Dromain C, Duran R, Halkic N, Sempoux C. Heterotopic gastric mucosa in a duplication cyst of the common hepatic duct mimicking cholangiocarcinoma. Int J Surg Pathol. 2018;26(1):84–8.CrossRef
10.
Zurück zum Zitat Kim Y, Jung MJ, Shin SJ. Heterotopic gastric mucosa in the common bile duct with cholangiocarcinoma. Int J Surg Pathol. 2018;26(8):745–8.CrossRef Kim Y, Jung MJ, Shin SJ. Heterotopic gastric mucosa in the common bile duct with cholangiocarcinoma. Int J Surg Pathol. 2018;26(8):745–8.CrossRef
11.
Zurück zum Zitat Imamura N, Kusashio K, Yasutomi J, Matsumoto M, Suzuki T, Iida A, Fushimi K, Furukawa A, Konishi T, Harano R, et al. A rare case of gastric metastasis from cholangio carcinoma. Gan To Kagaku Ryoho. 2019;46(13):2470–2.PubMed Imamura N, Kusashio K, Yasutomi J, Matsumoto M, Suzuki T, Iida A, Fushimi K, Furukawa A, Konishi T, Harano R, et al. A rare case of gastric metastasis from cholangio carcinoma. Gan To Kagaku Ryoho. 2019;46(13):2470–2.PubMed
Metadaten
Titel
Cholangiocarcinoma presenting as dysphagia and misdiagnosed as gastritis: a case report
verfasst von
Chao Wang
Baoyue Zhang
Runmei Peng
Zan Zuo
Hongzhong Cheng
Jun Zhu
Tianxing Chen
Zhengji Song
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Gastroenterology / Ausgabe 1/2022
Elektronische ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-022-02156-6

Weitere Artikel der Ausgabe 1/2022

BMC Gastroenterology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.